机构:[1]Chinese Acad Med Sci, Peking Union Med Coll, State Key Lab Cardiovasc Dis, Natl Ctr Cardiovasc Dis,Hypertens Ctr,FuWai Hosp, Beilishi Rd 167, Beijing 100037, Peoples R China[2]Peking Union Med Coll Hosp, Beijing, Peoples R China[3]Beijing Pinggu Hosp, Beijing, Peoples R China[4]Beijing Hosp, Beijing, Peoples R China[5]Kailuan Gen Hosp, Tangshan, Peoples R China[6]Shanxi Acad Med Sci, Shanxi Bethune Hosp, Taiyuan, Peoples R China山西白求恩医院[7]Shanxi Med Univ, Affiliated Hosp 1, Taiyuan, Peoples R China[8]Baotou Med Coll, Affiliated Hosp 2, Baotou, Peoples R China内蒙古科技大学包头医学院[9]Peoples Hosp Ji Xian Dist, Tianjin, Peoples R China[10]Dalian Med Univ, Affiliated Hosp 1, Dalian, Peoples R China大连医科大学附属第一医院[11]Omron Dalian, Dalian, Peoples R China[12]Xinjiang Med Univ, Affiliated Hosp 1, Urumqi, Peoples R China[13]Shantou Univ, Affiliated Hosp 2, Med Coll, Shantou, Peoples R China[14]Benxi Railway Hosp, Benxi, Peoples R China[15]Hongxinglong Ctr Hosp, Shuangyashan, Peoples R China[16]Hebei North Univ, Affiliated Hosp 1, Zhangjiakou, Peoples R China[17]Harbin Med Univ, Affiliated Hosp 1, Harbin, Peoples R China[18]Wuhan Univ, Renmin Hosp, Wuhan, Peoples R China[19]Kang Ya Hosp, Yiyang, Peoples R China[20]FuWai Yunnan Cardiovasc Hosp, Kunming, Yunnan, Peoples R China[21]Zhoukou City Cent Hosp, Zhoukou, Peoples R China[22]Sichuan Univ, West China Hosp, Chengdu, Peoples R China四川大学华西医院[23]Guangdong Cardiovasc Inst, Guangzhou, Peoples R China广东省人民医院[24]Xi An Jiao Tong Univ, Affiliated Hosp 1, Xian, Peoples R China[25]Natl Taiwan Univ Hosp, Cardiovasc Ctr, Taipei, Taiwan[26]Natl Taiwan Univ Hosp, Div Cardiol, Dept Internal Med, Taipei, Taiwan[27]Natl Taiwan Univ Hosp, Div Hosp Med, Dept Internal Med, Taipei, Taiwan[28]Jichi Med Univ, Sch Med, Shimotsuke, Tochigi, Japan
Background The appropriate target for systolic blood pressure to reduce cardiovascular risk in older patients with hypertension remains unclear. Methods In this multicenter, randomized, controlled trial, we assigned Chinese patients 60 to 80 years of age with hypertension to a systolic blood-pressure target of 110 to less than 130 mm Hg (intensive treatment) or a target of 130 to less than 150 mm Hg (standard treatment). The primary outcome was a composite of stroke, acute coronary syndrome (acute myocardial infarction and hospitalization for unstable angina), acute decompensated heart failure, coronary revascularization, atrial fibrillation, or death from cardiovascular causes. Results Of the 9624 patients screened for eligibility, 8511 were enrolled in the trial; 4243 were randomly assigned to the intensive-treatment group and 4268 to the standard-treatment group. At 1 year of follow-up, the mean systolic blood pressure was 127.5 mm Hg in the intensive-treatment group and 135.3 mm Hg in the standard-treatment group. During a median follow-up period of 3.34 years, primary-outcome events occurred in 147 patients (3.5%) in the intensive-treatment group, as compared with 196 patients (4.6%) in the standard-treatment group (hazard ratio, 0.74; 95% confidence interval [CI], 0.60 to 0.92; P=0.007). The results for most of the individual components of the primary outcome also favored intensive treatment: the hazard ratio for stroke was 0.67 (95% CI, 0.47 to 0.97), acute coronary syndrome 0.67 (95% CI, 0.47 to 0.94), acute decompensated heart failure 0.27 (95% CI, 0.08 to 0.98), coronary revascularization 0.69 (95% CI, 0.40 to 1.18), atrial fibrillation 0.96 (95% CI, 0.55 to 1.68), and death from cardiovascular causes 0.72 (95% CI, 0.39 to 1.32). The results for safety and renal outcomes did not differ significantly between the two groups, except for the incidence of hypotension, which was higher in the intensive-treatment group. Conclusions In older patients with hypertension, intensive treatment with a systolic blood-pressure target of 110 to less than 130 mm Hg resulted in a lower incidence of cardiovascular events than standard treatment with a target of 130 to less than 150 mm Hg. (Funded by the Chinese Academy of Medical Sciences and others; STEP ClinicalTrials.gov number, .) Intensive Blood-Pressure Control in Older Patients In 8511 Chinese patients 60 to 80 years of age with hypertension, intensive treatment (systolic blood-pressure target, 110 to <130 mm Hg) resulted in a lower incidence of cardiovascular events than standard treatment (target, 130 to <150 mm Hg). The two groups had similar incidences of adverse events, except for hypotension, which occurred more frequently with intensive treatment.
基金:
Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences [2016I2M-1-006, CI2021A00920]; Beijing Outstanding Young Scientist Program [BJJWZYJH01201910023029]; National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81630014, 81825002]
第一作者机构:[1]Chinese Acad Med Sci, Peking Union Med Coll, State Key Lab Cardiovasc Dis, Natl Ctr Cardiovasc Dis,Hypertens Ctr,FuWai Hosp, Beilishi Rd 167, Beijing 100037, Peoples R China
推荐引用方式(GB/T 7714):
Zhang Weili,Zhang Shuyuan,Deng Yue,et al.Trial of Intensive Blood-Pressure Control in Older Patients with Hypertension[J].NEW ENGLAND JOURNAL OF MEDICINE.2021,385(14):1268-1279.doi:10.1056/NEJMoa2111437.
APA:
Zhang, Weili,Zhang, Shuyuan,Deng, Yue,Wu, Shouling,Ren, Jie...&Cai, Jun.(2021).Trial of Intensive Blood-Pressure Control in Older Patients with Hypertension.NEW ENGLAND JOURNAL OF MEDICINE,385,(14)
MLA:
Zhang, Weili,et al."Trial of Intensive Blood-Pressure Control in Older Patients with Hypertension".NEW ENGLAND JOURNAL OF MEDICINE 385..14(2021):1268-1279